KinCon biolabs — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

KinCon biolabs is an Austrian biotech startup pioneering a live-cell biosensor platform for drug discovery. Its core technology, the KinCon biosensor, enables real-time, high-content analysis of protein conformational changes—particularly for kinases, nuclear receptors, p53, and E3 ligases—in response to drug candidates. The platform aims to accelerate the identification of mutation-specific therapeutics, with an initial focus on neurodegenerative disorders and oncology. As a private, pre-revenue company, KinCon operates as a platform technology provider, serving pharmaceutical and biotech partners through research collaborations and services.

OncologyNeurodegenerative Disorders

Technology Platform

Luciferase-based live-cell biosensors that measure drug-induced conformational changes in full-length proteins (kinases, nuclear receptors, p53, E3 ligases) for target engagement and activity analysis.

Opportunities

The platform addresses the high failure rate in drug discovery by providing predictive, live-cell data, creating significant demand from pharma partners.

Expansion into the high-growth targeted protein degradation (TPD) space with E3 ligase biosensors positions the company at the forefront of a major therapeutic modality.

The focus on mutation-specific profiling aligns perfectly with the expanding precision medicine market.

Risk Factors

Key risks include slow adoption of the new technology by established pharmaceutical companies, technical challenges in validating the platform across a broad range of complex targets, and reliance on securing sufficient funding to scale operations as a pre-revenue startup.

Competitive Landscape

KinCon competes with providers of traditional biochemical and cell-based assays (e.g., Cisbio, Promega) and newer functional cellular screening technologies. Its unique selling proposition is the direct measurement of native protein conformation in live cells. Competitors include companies like DiscoverX (now part of Eurofins) with complementary assay platforms, but KinCon's specific conformational focus is a differentiating niche.

More companies in Diagnostics & Precision Medicine →More companies in Austria →